Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug - Investor's Business Daily
Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug Investor's Business Daily Lilly’s Retatrutide Shows Significant Improvement In Weight Loss and Blood Sugar WSJ Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial Fierce Biotech Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Eli Lilly